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Immunotoxins (IT) are hybrid molecules comprised of an antibody
coupled chemically or genetically to a toxin or ribosome inactivat-
ing protein (RIP) such as saporin (Flavell, 1998; Kreitman, 1999;
Frankel et al, 2000). The antibody component allows for the 
selective delivery of the toxin to the surface of cells bearing the
target antigen. In order to kill the target cell it is an absolute 
requirement that the conjugate is internalized by receptor-
mediated endocytosis and that subsequently the toxin component
is routed to the appropriate intracellular compartment where trans-
location of the toxin component to the cytosol can take place.
Once in the cytosol RIPs such as saporin catalytically inactivate
28S ribosomal RNA via a highly specific N-glycosidase enzymat-
ic activity (Endo, 1988) that results in cessation of protein synthe-
sis in the cell and leads to apoptotic cell death (Bergamaschi et al,
1996). 
Arguably, the most important factor that theoretically limits the
therapeutic efficacy of immunotoxins that have no bystander effect
and which therefore have to exert their cytotoxic influence directly
on all cells in the tumour, is the heterogeneity of target antigen
expression within the global tumour cell population. Thus, relat-
ively small numbers of tumour cells down-regulated or negative
for the target antigen would escape killing by any single immuno-
toxin and if these surviving cells possess growth potential this
would lead to subsequent tumour re-growth. One way of over-
coming this problem would be to simultaneously target against
more than one target molecule on the tumour cell surface in the
expectation that multiple antigen-negative tumour cells would
occur with a much lower frequency than single antigen-negative
cells. There would also be the added bonus that targeting against
more than one antigen on the tumour cell surface would ensure
delivery of greater and therefore more effective quantities of the
cytotoxic agent carried by antibody to tumour cells that were
multiple antigen positive. Other factors such as the cell signalling
effects and recruitment of cytotoxic host effectors may also work
in conjunction to achieve an improved therapeutic effect when
combinations of antibody-based therapeutics are utilized. We have
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Summary Severe combined immunodeficient (SCID) mice injected i.v. with the human T-ALL cell line CCRF CEM (SCID-CEM mice) develop
within 50 days life-threatening multi-organ growth of leukaemia cells. The development of leukaemia in SCID-CEM mice treated with three 10 mg
i.v. doses of the anti-CD7 immunotoxin (IT) HB2-SAPORIN or the anti-CD38 IT OKT10-SAPORIN was significantly delayed compared with PBS
sham-treated animals but 90% of animals treated with either IT eventually developed disseminated leukaemia cell growth. In contrast treatment
of SCID-CEM mice with a combination of both ITs led not only to a significantly greater delay in time to leukaemia development but also in the
numbers of animals remaining leukaemia free (60%). The native HB2 and OKT10 antibodies (both murine IgG1 antibodies) exerted significant,
though relatively weak therapeutic effects, probably mediated through an antibody-dependent cellular cytotoxicity (ADCC) mechanism.
Moreover, there was no in vivo additivity of therapeutic effect when both antibodies were used in combination. Apparent, however, was that the
combination of HB2-SAPORIN IT with OKT10 antibody led to an intermediate therapeutic effect that was significantly greater than that obtained
when either was used alone but significantly less than that obtained when the two IT combination was utilized. This was similarly the case for the
combination of OKT10-SAPORIN IT with HB2 antibody though the effect was less pronounced in this instance. This result suggests that the
therapeutic effect of IT + antibody treatment results from an additivity between antibody-mediated delivery of saporin combined with a SCID
mouse NK cell-mediated ADCC attack on the target cell directed through target cell bound antibody Fc engagement with FcgRIII on the NK cell
surface. The combination of both ITs however gave the best therapeutic outcome in SCID-CEM mice probably as the result of (i) delivery of
greater amounts of saporin to target CEM cells positive for both CD7 and CD38, (ii) delivery of an effective dose of saporin to CEM cells
downregulated or negative for one of the target antigens and (iii) through ADCC mechanisms that interact additively with IT action. We have
previously proposed that combination IT therapy would be one means of overcoming the problem of heterogeneity of antigen expression within
a global tumour cell population and these additional findings support this and provide a further strengthening of the rationale for employing
cocktails of ITs for the treatment of human malignancies. © 2001 Cancer Research Campaign htt://www.bjcancer.com
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previously shown that therapy outcome in SCID mice xenografted
with the human B-cell lymphoma cell line Ramos is significantly
improved when a combination of anti-CD19 and anti-CD38
saporin ITs are used compared with when either IT is used indi-
vidually (Flavell et al, 1995). Indeed we have further shown that a
3 IT combination with anti-CD19, -CD22 and -CD38 specificities
can completely cure SCID-Ramos mice (Flavell et al, 1997).
Studies by others have similarly shown that combinations of ITs
are more effective (Lambert et al, 1985; Strong et al, 1985). These
findings allow us to feel optimistic that such a therapeutic
approach may be of real practical benefit in achieving better and
more robust response rates in patients with this type of
immunotherapeutic and justify further preclinical evaluation. In
the present study we demonstrate that a combination of anti-CD7
and anti-CD38-saporin ITs are significantly more effective thera-
peutically in SCID mice xenografted with the human CD7+
CD38+ T-ALL cell line CCRF CEM than the individual ITs when
used individually, thus confirming in a completely different tumour
system our original findings with the B-cell lymphoma cell line
Ramos (Flavell et al, 1995, 1997) and therefore further reinforcing
the rationale for developing this approach for clinical trials. 
MATERIALS AND METHODS 
SCID mice 
Pathogen free CB.17 scid/scid (SCID) mice (Bosma et al, 1983) of
both sexes 6–10 weeks of age were produced from our own
breeding colony and used in all the experimental work described
here. All animals described in these studies are strictly maintained
according to British Home Office regulations under the Animals
(Scientific Procedures) Act 1986. The breeding colony is main-
tained under sterile conditions inside a laminar flow isolator and
animals are housed on sterile bedding and provided with sterile
water and food ad libitum. Animals for experimental use were
transferred out from the isolator to autoclaved filter top micro
isolator cages and housed on sterile bedding as 5 single sex
animals per cage. These animals were also provided with sterile
water and food ad libitum and all manipulations with these
animals were carried out in a laminar flow hood by personnel
using aseptic techniques. During all procedures involving animals
the UKCCCG Guidelines for the Welfare of animals in
Experimental Neoplasia were strictly adhered to minimize stress
or suffering (Workman et al, 1998). 
CCRF CEM human T-cell acute lymphoblastic
leukaemia cell line 
The cell line CCRF CEM cell line was derived from the peripheral
blood of a paediatric patient with T-cell acute lymphoblastic
leukaemia (Foley et al, 1965) and obtained from the American
Tissue Culture Collection (ATCC, Bethesda, MD). Cells were
maintained in the logarithmic phase of growth in antibiotic-free
RPMI 1640 medium containing 10% fetal calf serum and supple-
mented with 1 mM sodium pyruvate and glutamine (hereafter
referred to as R10 medium). 
Antibody production 
The hybridoma clone HB2 producing anti-CD7 antibody was
produced by culturing HB2 hybridoma cells in an Endotronics
Acusyst R hollow fibre bioreactor system (Endotronics Inc,
Minneapolis, MN). The anti-CD38 antibody OKT10 was produced
by culturing OKT10 hybridoma cells on an Integra Technomouse
hollow fibre system (Integra Biosciences, Cramlington, UK) as per
manufacturer’s instructions. Both antibodies are of the IgG1subclass.
Antibody was purified from culture supernatants by DEAE ion
exchange chromatography and size exclusion chromatography on
Sepharose S200HR. F(ab)2 fragments of each antibody were
produced by pepsin digestion utilizing a kit from Pierce (Perbio
Sciences UK Ltd, Tattershall). The specificity of each antibody or
respective F(ab)2 fragment was confirmed by flow cytometry and by
immunohistochemical staining of sections of frozen tonsil. 
Saporin production 
Seeds of the Soapwort plant Saponaria officinalis were kindly
supplied by Chiltern Seeds, Ulverston, Cumbria, UK. Saporin was
extracted from seeds by the method of Stirpe (Stirpe et al, 1983)
and purified to homogeneity by a combination of cation exchange
chromatography on carboxymethyl-Sepharose and gel filtration on
Sephacryl-S200HR (Sigma Chemical Co, Poole, UK). The final
product gave a single band of 29 500 daltons on SDS-PAGE and
was immunoreactive on ELISA with both polyclonal and mono-
clonal anti-saporin antisera. 
Immunotoxin construction 
The immunotoxins HB2-SAPORIN (anti-CD7) and OKT10-
SAPORIN (anti-CD38) were constructed by conjugating HB2 or
OKT10 antibody to saporin with the heterobifunctional cross
linking reagent N-succinimidyl 3-(2-pyridyldithio) propionate
(SPDP) (Pharmacia, Uppsala, Sweden) as described previously
(Thorpe et al, 1985). Immunotoxins prepared in this way
contained a non-hindered disulphide bond between antibody and
saporin. Free antibody was removed from the immunoconjugates
by carboxymethyl-Sepharose (Sigma Chemical Co, Poole, UK)
cation exchange chromatography as described previously
(Lambert et al, 1985). Purified immunotoxins were dialysed into
PBS pH 7.2, sterilized by passage through a 0.2 mm filter and
stored deep frozen in 100 mg aliquots at 280˚C. 
Flow cytometry 
Dual colour analysis for the cell surface expression of CD7 and
CD38 by CCRF CEM cells was measured on an EPICS XL flow
cytometer (Beckman Coulter UK, High Wycombe) equipped with
Coulter PC-based analytical software. CCRF cells were first
stained at 4˚C with OKT10 antibody (10 mg ml–1 in PBS
containing 0.1% sodium azide) followed by a 1:20 dilution of
FITC labelled F(ab)2 goat anti-mouse immunoglobulin (Sigma
Chemical Co, Poole, Dorset). Cells were then double-labelled by
incubation for a further 30 minutes at 4˚C with biotinylated HB2
antibody (10 mg ml–1) in PBS also containing 0.1% sodium azide.
Cells were then washed twice and phycoerythrin-labelled strepta-
vidin (Dako, High Wycombe, Bucks) at a 1:100 dilution was incu-
bated with the cell pellet for 20 min at 4˚C after which analysis
was carried out on a Coulter EPICS XL flow cytometer. 
Single colour flow cytometric analysis was similarly conduced
on single cell suspensions of solid CCRF CEM tumours removed
from IT or PBS sham-treated animals but using HB2 and OKT10
antibodies directly labelled with FITC. Combination immunotoxin therapy of leukaemia 573
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SDS-PAGE analysis 
SDS PAGE analysis (Laemmli, 1970) was used to confirm the
purity of antibody, saporin and ITs. 5% non-reducing gels with 3%
stacks were routinely used for separations. 
Protein synthesis inhibition assay 
The ability of each IT, native antibody or saporin to inhibit protein
synthesis in target CCRF CEM cells was evaluated by a [3H]-
leucine incorporation assay as described previously (Flavell et al,
1995) (CN Pharmaceuticals Ltd, Basingstoke).
Cell outgrowth assay 
CCRF CEM cells (1 ´ 105 cells) were cultured in R10 medium in
T25 culture flasks in the presence of given concentrations of IT,
antibody or combinations of both. Control cultures were grown in
R10 medium only. Viable haemocytometer cell counts using Trypan
blue exclusion were carried out on cultures at regular intervals. 
Chromium release assay 
51Cr (Amersham-Pharmacia, Amersham) release assays were per-
formed as described previously (Flavell et al, 1998) in order to deter-
mine and quantify the extent of complement-dependent cytotoxicity
(CDC) or antibody-dependent cellular cytotoxicity mediated by each
antibody or each IT construct against target Ramos cells. 
Establishment of CCRF CEM leukaemia in SCID mice 
Two million CCRF CEM cells were injected into the tail vein (i.v.)
of SCID mice in a 200 ml volume of R10 medium. In all therapy
studies cells were injected 7 days prior to commencing treatment
with IT or antibody. 
Therapy protocols 
7 days after i.v. injection of CCRF CEM cells, appropriate groups
were treated with three 10 mg doses of either IT, antibody or a
combination of both given as a bolus injection (in a 200 ml volume
of PBS) into a tail vein on alternate days (i.e. days 7, 9 and 11).
Where a combination of two ITs, two antibodies or an IT plus an
antibody was used the 10 mg dose was comprised of 5 mg of each
component part. For antibody treatment the dose was comprised of
8 mg antibody plus 2 mg saporin, this ratio being approximately
representative of the molar equivalent content of each component
contained within the 10 mg dose of IT. 
All animals were monitored twice daily for the duration of the
study and strictly defined endpoints were enforced as per recom-
mendations under the UKCCCR guidelines (Workman et al, 1998)
to ensure that no animal suffered undue or unnecessary stress or
pain during the course of the study. Thus, animals showing any
early identifiable signs of becoming unwell were killed humanely
and full post-mortem examinations conducted to confirm the
presence of tumour. 
Statistical analysis 
Log-Rank analysis (Peto’s method) using the SOLO statistics soft-
ware package (BMDP Statistical Software, Los Angeles, CA,
USA) was used to determine if there were any significant differ-
ences between the various therapy groups. P values of 0.05 or less
were considered as statistically significant in these studies. 
Histopathology 
All tissues obtained at post-mortem from animals sacrificed inter-
currently or killed electively at termination of the experiment were
fixed in 10% neutral buffered saline (NBFS), processed and
embedded in paraffin wax. Sections were cut and stained with
haematoxylin and eosin (H&E) or immunostained with the anti-
CD43 antibody DF-T1 that identifies human T-cells in paraffin
section (Stross et al, 1989). 
RESULTS 
Growth of CCRF CEM leukaemia in SCID mice 
The pattern of growth of CCRF CEM in non-conditioned SCID
mice was virtually identical to that described by us previously for
the growth of HSB-2, another human T-ALL cell line (Morland et
al, 1994). In summary, SCID mice injected with two million CCRF
CEM cells developed multi-organ involvement with observable
growth of solid CCRF CEM tumours in liver, kidney, bone
marrow, meninges and elsewhere. Animals injected with this
number of CCRF CEM cells were electively killed between 36 and
49 days when early symptoms of disease appeared. The presence
of CCRF CEM tumour growth was confirmed in these animals by
post mortem and where necessary (i.e. when no gross tumour was
visible) by histopathology and immunohistochemical staining
with the anti-CD43 antibody DF-T1. SCID-CEM mice from the
different treatment regimes that were killed inter-currently during
the course of the experiment all had demonstrable tumour growth.
Animals that survived to 300 days that were electively killed at
this time showed no gross or microscopic evidence of tumour
growth. 
Expression of CD7 and CD38 by CCRF CEM cells 
The results of two-colour flow cytometric analysis of CCRF CEM
cells for CD7 and CD38 expression are shown in Figure 1. The
vast majority (99.59%) of CEM cells possessed a double antigen
positive (CD7+ CD38+) immunophenotype with 0.04% with a
CD7+ CD38- and 0.29% with a CD7-CD38+ immunophenotype.
A tiny subpopulation of 0.09% were double antigen negative
(CD7- CD38-). 
Single cell suspensions of CCRF CEM tumours growing in two
SCID-CEM mice from each group treated with each individual IT
with a combination of both ITs or sham-treated with PBS were
stained with HB2 or OKT10 antibody for flow cytometry. CCRF
CEM tumours from the IT-treated animals were positive for CD7
and CD38 expression at similar levels exhibited by cells taken
from PBS sham-treated control animals (data not shown) and we
can conclude therefore that either single or combination IT treat-
ment did not select for antigen-negative tumour cell variants. 
Lysis of Ramos cells by HB2 and OKT10 antibody and
respective IT constructs in CDC and ADCC 
Chromium release assays were used to determine whether
HB2 and OKT10 antibody or their respective IT constructs werecapable of eliciting complement-dependent cytotoxicity (CDC)
via the classical pathway following antibody binding to the target
cell surface or antibody-dependent cellular cytotoxicity (ADCC)
mediated by SCID mouse splenocytes as effectors. Antibodies or
ITs used singly or in pair combinations had no lytic activity in the
CDC assay system. In contrast very clear antibody or IT dose-
dependent lysis of CCRF CEM cells occurred when SCID mouse
splenocytes were included in an ADCC assay (target cell:effector
cell ratio of 1:70) (Figure 2). HB2-SAPORIN and OKT10-
SAPORIN ITs each exerted similar lytic activities in ADCC
though there was a greater dose dependency seen with OKT10-
SAPORIN (Figure 2). Both ITs used in combination exerted
greater lytic activity than each individual IT particularly at the
mid-level of the concentration range studied. An irrelevant IT,
BU12-SAPORIN identifying the CD19 molecule that is not
expressed by CRF CEM cells did not cause any lysis of these cells
in ADCC. Near identical lysis profiles were obtained when intact
HB2 and OKT10 antibodies were used in place of the respective
IT (data not shown). A F(ab)2 fragment of each antibody used over
the same molar concentration range did not cause lysis of CCRF
CEM cells in ADCC demonstrating an absolute requirement for
the Fc domain of antibody for lysis (data not shown). 
Inhibition of protein synthesis in CCRF CEM cells by
immunotoxins and antibodies 
The effects of increasing molar concentrations of HB2-SAPORIN
IT, OKT10-SAPORIN IT, HB2 antibody and OKT10 antibody
used individually or in various combinations on protein synthesis
levels in target CCRF CEM cells are summarized in Table 2.
OKT10-SAPORIN performed best against CCRF CEM cells with
an achieved IC50 of 3.8 ´ 10211 M representing a 2895-fold
increase over saporin. HB2-SAPORIN gave a 1549-fold increase
with an achieved IC50 of 7.1 ´ 10211 M. A mixture of both
immunotoxins performed in an intermediate fashion with an
achieved IC50 of 5.9 ´ 10211 M (1864-fold increase). HB2 or
OKT10 antibodies used individually or in combination over the
same concentration range had no significant effect on protein
synthesis levels in CCRF CEM cells (data not shown). When
a mixture of OKT10-SAPORIN plus HB2 antibody or HB2-
SAPORIN plus OKT10 antibody was employed, performance was
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Figure 1 Two colour flow cytometric analysis of CD7 and CD38 expression
by the human T-cell acute lymphoblastic leukaemia cell line CCRF CEM. The
percentage of cells with a given immunophenotypic expression of CD7/CD38
is shown in each quadrant 
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Figure 2 Lysis of CCRF CEM target cells in an ADCC chromium release
assay utilizing SCID mouse splenocytes as effectors (target:effector ratio
1:70) in the presence of increasing molar concentrations of HB2-SAPORIN IT
(n), OKT10-SAPORIN IT (l), a combination of both ITs (s), or the irrelevant 
anti-CD19 IT BU12-SAPORIN (n n) 
Table 1 Summary of experimental SCID mouse groups and therapy outcomes 
Treatment group Treatment No. animals Mean survival (days)a % Survivorsb
a PBS 10 40.5 0 
b HB2-SAPORIN IT 10 83.7 10 
c OKT10-SAPORIN IT 10 109.0 10 
d HB2-SAPORIN + OKT10-SAPORIN ITs 10 231.6 60 
e HB2 Ab 10 47.0 0 
f OKT10 Ab 10 94.6 10 
g HB2 Ab + OKT10 Ab 10 90.6 10 
h HB2-SAPORIN IT + OKT10 Ab 10 163.6 40 
i OKT10-SAPORIN IT + HB2 Ab 10 137.5 20 
aMean survival calculated at termination of study at 300 days. bPercentage survivors at 300 days. reduced to a level below that seen when each IT was used
individually, with achieved IC50 values of 8.8 ´ 10211 M and
1.5  ´ 10210 M, respectively (Table 2). 
Inhibition of CCRF CEM cell growth by immunotoxins
and antibodies 
The results for long-term outgrowth of CCRF CEM cells exposed
continuously to HB2-SAPORIN or OKT10-SAPORIN at a
concentration of 1 mg ml21 or to a combination of both ITs each at
0.5 mg ml–1 (i.e. 1 mg ml21 total) are shown in Figure 3. Each indi-
vidual IT used at this concentration delayed the growth of CCRF
CEM cells by between 20 to 30 days compared to medium controls
but growth did eventually occur by this time. In contrast, growth of
CCRF CEM cells was completely inhibited when cells were
exposed to an equivalent total concentration of a combination of
both ITs with no living cells detectable in these cultures at day 50.
CCRF CEM cells growing out following exposure to either indi-
vidual IT still expressed CD7 and CD38 at near normal levels and
were still sensitive to the cytotoxic effects of both ITs in protein
synthesis inhibition assays (data not shown). HB2 or OKT10 anti-
body used individually or in combination at the same total concen-
tration of 1 mg ml21 had no significant effect on CCRF CEM
growth (data not shown). The combination of HB2-SAPORIN with
OKT10 antibody or OKT10-SAPORIN with HB2 antibody were
both less effective at inhibiting CCRF CEM outgrowth than were
the individual ITs with cell growth occurring earlier (Figure 3). 
Immunotoxin and antibody therapy of SCID mice with
disseminated CCRF CEM leukaemia 
The therapeutic effects of the anti-CD7 IT, HB2-SAPORIN or of
the anti-CD38 IT, OKT10-SAPORIN or of native antibody used
individually or in combination, or a combination of a single
immunotoxin with a single antibody were investigated in groups of
SCID mice bearing disseminated CCRF CEM leukaemia. Details
of the various therapy groups are given in Table 1 together with a
summary of the mean survival times and percentage survivors in
each treatment group. A comparison made between the different
therapy groups for statistically significant differences was under-
taken by log-rank analysis and these data are shown in Table 3. 
The Kaplan-Meier curves obtained for SCID-CEM mice treated
with each individual IT or a combination of both ITs are shown in
Figure 4. Control animals (group a) given PBS sham-treatment all
developed symptomatic disseminated CCRF CEM leukaemia by
49 days. Treatment with HB2-SAPORIN (group b) led to a signif-
icant prolongation in time to symptomatic disease appearance
(mean time of 83.7 days) compared with controls (P = 0.0012)
though 90% of these animals had eventually developed sympto-
matic disseminated leukaemia by day 81. OKT10-SAPORIN
(group c) gave a more prolonged survival time (mean 109 days)
compared with the PBS sham-treated control group. When both
ITs were used in combination (group d) there was a highly signif-
icant improvement in both mean survival time (231.6 days) and in
the proportion of animals that remained disease-free (60% at 300
days). The difference between the PBS sham-treated group (group
a) and the combination IT group (group d) was highly significant
(P = 0.0003). 
We also examined the therapeutic effects of the native HB2 and
OKT10 antibodies in the SCID-CEM model (Tables 1 and 3). HB2
antibody exerted a small, though significant (P = 0.0293), thera-
peutic effect in SCID-CEM mice (group e) prolonging the time to
Combination immunotoxin therapy of leukaemia 575
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Table 2 In vitro inhibition of protein synthesis in target CEM cells by
immunotoxins used singly or in combination or by a single immunotoxin used
in combination with a single antibody 
Treatment IC50 (M)a Fold-increaseb
HB2-SAP IT 7.1 ´ 10211 1549 
OKT10-SAP IT 3.8 ´ 10211 2895 
HB2-SAP IT + OKT10-SAP IT 5.9 ´ 10211 1864 
HB2-SAP IT + OKT10 Ab 1.5 ´ 10210 733 
OKT10-SAP IT + HB2 Ab 8.8 ´ 10211 1250 
SAPORIN ALONE 1.1 ´ 1027 – 
aIC50 calculated as the molar concentration of IT needed to achieve 50%
inhibition of 3H-leucine incorporation compared with untreated control cells. 
bFold increase calculated as IC50 saporin alone/IC50 treatment. 
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SAPORIN (n), OKT10-SAPORIN (s), a combination of both HB2-SAPORIN
+ OKT10-SAPORIN (l) a combination of HB2-SAPORIN + OKT10 antibody
(n n), OKT10-SAPORIN + HB2 antibody (l l) or medium control (s s). Cultures
exposed to a single reagent at a concentration of 1 mg ml–1. When a
combination of two reagents was employed the final concentration of both
reagents combined was 1 mg ml21 (i.e. 0.5 mg ml21 of each) 
0
0
20
40
60
80
100
20
%
 
a
l
i
v
e
40 60 80
Days
a
bc
d
h
i
100 120 140 160 180 200 300
Figure 4 Kaplan-Meier plots for SCID-CEM mice injected on day 1 with two
million CCRF CEM cells and treated with 3 i.v. injections of 10 mg each
(given on days 7, 9 and 11) of HB2-SAPORIN (n), OKT10-SAPORIN (n n), a
combination of both ITs (l) HB2-SAPORIN + OKT10 antibody (l l), OKT10-
SAPORIN + HB2 antibody (s s), or PBS sham-treated (s). Where animals
received a combination of two reagents totalling 10 mg dose this was
comprised of 5 mg of each component. Group identification letters, refer to
Table 1symptomatic leukaemia appearance to 47 days but with all animals
developing leukaemia by day 78. Comparison of HB2 antibody-
treated animals with HB2-SAPORIN treated animals showed that
the therapeutic effect of this IT was significantly greater than the
antibody-mediated effect (P = 0.018). OKT10 antibody (group f)
exerted a better and more significant therapeutic effect than HB2
antibody, prolonging the mean time to symptomatic leukaemia
appearance for animals in this group to 94.6 days with a significance
level of P = 0.0015 when compared with PBS sham-treated control
animals. The therapeutic effect of OKT10 antibody was however
significantly less than that exerted by the OKT10-SAPORIN IT
(P = 0.0015). The time to leukaemia appearance characteristics of
animals treated with a combination of HB2 and OKT10 antibodies
(group g) was virtually identical to that for those animals treated
with OKT10 antibody alone and there was therefore no therapeutic
gain to be had from treating with a combination of both antibodies. 
In order to ascertain whether it might be an additive interaction
between one of the IT components and one of the antibody com-
ponents present in the two combination IT treatment that led to the
significant improvement in therapeutic effectiveness, we undertook
studies in which groups of SCID-CEM mice were treated with an
IT/antibody pair. The results of this study are also shown in Figure 4.
The therapeutic effectiveness of HB2-SAPORIN + OKT10 antibody
(group h) or OKT10-SAPORIN + HB2 antibody (group i) treatments
was significantly below that obtained for the combination of both ITs
C (group d). However, the combination of HB2-SAPORIN IT.
OKT10 antibody (group h) did significantly increase the therapeutic
effects above that obtained when either HB2-SAPORIN IT (group b)
or OKT10 antibody (group f) were used alone. 
DISCUSSION 
The main finding to emerge from this study is that two saporin
immunotoxins directed against the CD7 and CD38 antigens on the
surface of the human T-cell acute lymphoblastic leukaemia cell
line CCRF CEM, perform significantly better therapeutically
in SCID-CEM mice when used in combination than when used
individually. Those leukaemias that did eventually emerge in the
two IT cocktail still expressed both target antigens demonstrating
that therapy had not selected for antigen-negative variants as has
been the case with anti-idiotypic antibodies directed against the
cell surface immunoglobulin of B-cell tumours (Glennie et al,
1987). As we have argued previously antigen-expressing tumour
cells may have avoided killing by IT either because a small
subpopulation of the global tumour cell population were epigenet-
ically down-regulated for antigen expression at the time of treat-
ment or alternatively because small numbers of leukaemia cells
were at locations inaccessible to IT at the time of treatment. We
reason that it was from these ‘escapee’ cells that tumours eventu-
ally emerged. The in vivo findings were also reflected in a long
term in vitro outgrowth assay where the combination of two ITs
completely inhibited target cell proliferation. However, this was
not the case in a short-term protein synthesis inhibition assay
where there was actually a reduction in apparent cytotoxicity
toward CEM cells when a combination of two ITs was employed.
Curiously, as exemplified in the present and other studies (Flavell
et al, 1997), we have never been able to show any improvement in
IC50 values when combinations of ITs are used against target cells
expressing the appropriate target antigens. 
The present study has confirmed in a different model tumour
system very similar findings, which we originally made with the
human B-cell lymphoma cell line Ramos when targeted against
with a combination of anti-CD19 and -CD38-saporin ITs (Flavell
et al, 1995). In the instance of the SCID-Ramos model it was
found that the improved therapeutic benefit was entirely due to an
immunotoxin-mediated effect, as combination pairs of IT + anti-
body (i.e. anti-CD19 IT + anti-CD38 antibody or anti-CD38 IT +
CD19 antibody) did not improve the therapeutic outcome. This
finding was contrary to that of Ghetie et al (1992) who were able
to demonstrate that the anti-CD19 antibody HD37 used in combi-
nation with an anti-CD22 ricin A chain IT (RFB4-dgR) was
equally as effective therapeutically in SCID mice xenografted with
the human B-cell lymphoma cell line Daudi as was a specificity
equivalent combination of two ITs. Additional work from the same
576 DJ Flavell et al  
British Journal of Cancer (2001) 84(4), 571–578 © 2001 Cancer Research Campaign
Table 3 Comparison of the various treatment groups for mean survival and for statistically significant
differences by Log-Rank analysis 
Treatment 1 vs Treatment 2 Mean survival (days) P value 
1v s 2  
a b 40.5 83.7 0.0012 
a c 40.5 109.0 0.0015 
a d 40.5 231.6 0.0003 
a e 40.5 47.0 0.0293 
a f 40.5 94.6 0.0018 
a g 40.5 90.6 0.0022 
b c 83.7 109.0 0.0697 
b d 83.7 231.6 0.0028 
c d 109.0 231.6 0.0043 
b e 83.7 47.0 0.0180 
c f 109.0 94.6 0.0015 
d g 231.6 90.6 0.0033 
e g 47.0 90.6 0.0203 
e f 47.0 94.6 0.0195 
g f 90.6 94.6 0.9990 
d h 231.6 163.6 0.1698 
d I 231.6 137.5 0.0286 
h I 163.6 137.5 0.7656 
i g 137.5 90.6 0.1478 Combination immunotoxin therapy of leukaemia 577
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group showed that it was the anti-proliferative signalling effects of
CD19 antibodies in conjunction with toxin-mediated cytotoxicity
delivered via an anti-CD22 antibody that actually augmented the
therapeutic efficacy (Ghetie et al, 1994). 
In separate, though related studies we have also shown that the
anti-CD7 immunotoxin HB2-SAPORIN exerts its therapeutic
effects against the human T-ALL cell line HSB-2 growing in SCID
mice via two separate mechanisms; firstly through delivery of the
rip saporin to cells expressing the target CD7 molecule on their
surface and secondly through an antibody-dependent cellular cyto-
toxicity (ADCC) mechanism mediated by SCID mouse NK or
NK-like cells (Flavell et al, 1998). It is also evident in the present
study that HB2 (anti-CD7) antibody exerted a small therapeutic
effect in SCID-CEM mice manifest as a significant increase in the
time to symptomatic leukaemia appearance but without being
capable of effecting cures. OKT10 antibody performed somewhat
better achieving a significantly greater prolongation in time to
symptomatic leukaemia appearance but with 90% of the animals
still eventually developing disseminated leukaemia. Both of these
naked antibodies probably mediate their in vivo therapeutic effects
via ADCC and the in vitro chromium release results presented here
show demonstrably that both antibodies and ITs can evoke ADCC.
These results are very similar to those obtained with the anti-CD19
antibody BU12 and same anti-CD38 antibody in SCID mice
bearing the CD19+ CD38+ human B-cell lymphoma cell line
Ramos (Flavell et al, 1995). In both described tumour systems it
therefore appears that anti-CD38 antibody performs therapeut-
ically better than either the anti-CD19 antibody in the SCID-
Ramos model, or the anti-CD7 antibody in the SCID-CEM system.
As all 3 antibodies belong to the same subclass (IgG1) and as
expression levels of all 3 target molecules are very similar, it is
therefore unclear why antibody directed against CD38 on the
tumour cell surface should be more effective than anti-CD7 anti-
body. It may be that the topography of CD38 on the cell surface or
its manner of insertion into the membrane renders the target cell
more susceptible to cytolysis by ADCC directed against this mole-
cule. In a previous study in SCID-Ramos mice we demonstrated
that a combination pair of anti-CD19 IT + anti-CD38 antibody or
anti-CD38 IT plus anti-CD19 antibody did not exert any improved
therapeutic effect above that seen with the individual IT present in
the cocktail (Flavell et al, 1995). Thus, we concluded that the
significantly improved therapeutic effect obtained with the combi-
nation of anti-CD19 and anti-CD38 ITs in SCID-Ramos mice was
not due to antibody signalling such as has been described for the
SCID-Daudi model (Ghetie et al, 1992) or due to cytotoxic
effector recruitment exerted by the antibody component combined
with cytotoxicity due to toxin delivery via IT (Flavell et al, 1998). 
The current results described in this SCID-CEM model are
therefore somewhat different than our previous findings in the
SCID-Ramos model. In the current study it is clear that a combina-
tion of anti-CD7 IT plus anti-CD38 antibody improves the thera-
peutic outcome, though the effect is still significantly lower than
that obtained when the two specificity equivalent ITs are used in
combination. A similar effect was observed with anti-CD38 IT
combined with anti-CD7 antibody but this was less pronounced.
Having previously shown that it is ADCC mediated by SCID
mouse NK or NK-like cells that acts additively with the anti-CD7
IT HB2-SAPORIN IT to achieve the final therapeutic effect in
SCID mice bearing the human T-cell leukaemia HSB-2 (Flavell et
al, 1998) it is entirely possible that a similar effect is operating in
the described SCID-CEM model. Indeed the in vitro results
presented here demonstrate that both naked antibody and equiva-
lent ITs can efficiently mediate the lysis of CCRF CEM cells in
ADCC but not CDC obviating a role for complement. Neither is
there any direct evidence from the data presented here that direct
cell signalling mediated by ligation of CD7 or CD38 by antibody
has any significant influence on CCRF CEM cell proliferation or
viability. We therefore hypothesize that it must be a host effector
mechanism(s) such as ADCC driven by engagement of SCID
mouse NK cell FcgRIII with the Fc portion of the antibody compo-
nent of the HB2-SAPORIN or OKT10-SAPORIN IT in conjunc-
tion with saporin-mediated cytotoxicity delivered by IT that is
likely responsible for the improved therapeutic performance of the
IT + antibody combinations. This hypothesis is further strength-
ened by the observation made in the present study that lysis of
CCRF CEM cells is increased when combination pairs of ITs or
antibodies are employed. However, the fact that the therapeutic
effect of the IT + antibody combination is significantly less than
that obtained with the two IT combination indicates that other
factors must be contributing to the therapeutic mechanism operat-
ive with the two IT combination. In conclusion we hypothesize
that the combination of the two ITs used in the current study recogn-
izing CD7 or CD38 exert an improved therapeutic efficacy for 
any one or possibly all of the following individual reasons: (i) that
greater and therefore presumably more effective quantities of
saporin are delivered to CEM cells that express both the CD7 and
CD38 target molecules, (ii) that an effective dose of saporin is still
delivered to those CEM cells that are down-regulated or negative
for a single target antigen and (iii) that ADCC mechanisms may
exert their influence more effectively when two different cell
surface molecules are targeted against and that this may then work
additively together with the selective target cell cytotoxicity deliv-
ered by IT. It must be kept in mind that this is a model system that
has provided some proof of principle but that ITs constructed
with mouse IgG1 would not necessarily efficiently recruit human
effector cells (ie human FcgRIII bearing NK-cells and
macrophages). Therefore some of the beneficial effects described
here with mouse antibody-based molecules would not operate in
human disease. To achieve this it would be necessary to engineer
into the IT constructs human Fc domains that could efficiently
recruit human effectors. 
We have previously proposed that combination IT therapy
would be one means of overcoming the problem of heterogeneity
of antigen expression within a global tumour cell population.
These additional findings support this hypothesis and provide a
further strengthening of the rationale for employing cocktails of
ITs for the treatment of human malignancies. 
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